Bill & Melinda Gates Foundation and Amplitude Ventures led a $35m Series A round in Radiant Biotherapeutics.

Bill & Melinda Gates Foundation, an American private foundation, and Amplitude Ventures, an investment firm, led a $35m Series A round in Radiant Biotherapeutics, a preclinical biotechnology company, with participation from BDC Capital, abrdn, FACIT, Alexandria Venture Investments and Toronto Innovation Acceleration Partners. “These supportive investors share our vision of delivering powerful, multi-functional biologics with the potential to advance treatments for patients suffering from debilitating and life-threatening illnesses. This investment enables us to further demonstrate the unique power and breadth of our platform across multiple therapeutic areas with a focus in oncology, inflammation and immunology, and global health and infectious disease including HIV,” Arthur J. Fratamico, Radiant President and CEO.